Urszula Częścik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Urszula Częścik has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Anna Baraniak
Department of Pharmaceutical Microbiology and Laboratory Diagnostics, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland
1 shared publication - Anna Pogorzelska
National Medicines Institute
1 shared publication - Elżbieta Bednarek
Falsified Medicines and Medical Devices Department, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland
1 shared publication - Jan Cz. Dobrowolski
Institute of Nuclear Chemistry and Technology, 16 Dorodna-Street, 03-195 Warsaw, Poland
1 shared publication - Joanna E. Rode
Laboratory for Spectroscopy, Molecular Modeling and Structure Determination Institute of Nuclear Chemistry and Technology Dorodna 16, 03–195 Warsaw Poland
1 shared publication - Karolina Wegrzynska
Department of Pharmaceutical Microbiology and Laboratory Diagnostics, National Medicines Institute, 00-725 Warsaw, Poland
1 shared publication
Latest Publications
- Open Access
- 28 May 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (25) , 18080-18092
Tricarbonyl rhenium(i) complexes with 8-hydroxyquinolines: structural, chemical, antibacterial, and anticancer characteristics
Twelve tricarbonyl rhenium(I) complexes in the ‘2 + 1’ system with the anionic bidentate N,O-donor ligand (deprotonated 8-hydroxyquinoline (HQ) or its 2-methyl (MeHQ) or 5-chloro (ClHQ) derivative) and neutral N-donor diazoles (imidazole (Him), 2-methylimidazole (MeHim), 3,5-dimethylpyrazole (Hdmpz), and 3-phenylpyrazole (HPhpz)) were synthesized: [Re(CO)3(LN,O)LN] (LN,O = Q−, MeQ−, ClQ−; LN = Him, MeHim, Hdmpz, HPhpz). Their crystal structures were determined by the scXRD method, compared with the DFT-calculated ones, and characterized by analytical (EA) and spectroscopic techniques (FT-IR, NMR, and UV-Vis) interpreted with DFT and TD-DFT calculations. Most of the Re(I) complexes did not show relevant antibacterial activity against Gram-negative and Gram-positive bacterial strains. Only [Re(CO)3(MeQ)Him] demonstrated significant action 4-fold better against Gram-negative Pseudomonas aeruginosa than the free MeHQ ligand. The cytotoxicity of the compounds was estimated using human acute promyelocytic leukemia (HL-60), ovarian (SKOV-3), prostate (PC-3), and breast (MCF-7) cancer, and breast non-cancerous (MCF-10A) cell lines. Only HQ and ClHQ ligands and [Re(CO)3(Q)Hdmpz] complex had good selectivity toward MCF-7 cell line. HL-60 cells were sensitive to all complexes (IC50 = 1.5–14 μM). Still, pure HQ and ClHQ ligands were slightly more active than the complexes.
- 28 May 2024
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (25) , 18080-18092
Open AccessTricarbonyl rhenium(i) complexes with 8-hydroxyquinolines: structural, chemical, antibacterial, and anticancer characteristics
Twelve tricarbonyl rhenium(I) complexes in the ‘2 + 1’ system with the anionic bidentate N,O-donor ligand (deprotonated 8-hydroxyquinoline (HQ) or its 2-methyl (MeHQ) or 5-chloro (ClHQ) derivative) and neutral N-donor diazoles (imidazole (Him), 2-methylimidazole (MeHim), 3,5-dimethylpyrazole (Hdmpz), and 3-phenylpyrazole (HPhpz)) were synthesized: [Re(CO)3(LN,O)LN] (LN,O = Q−, MeQ−, ClQ−; LN = Him, MeHim, Hdmpz, HPhpz). Their crystal structures were determined by the scXRD method, compared with the DFT-calculated ones, and characterized by analytical (EA) and spectroscopic techniques (FT-IR, NMR, and UV-Vis) interpreted with DFT and TD-DFT calculations. Most of the Re(I) complexes did not show relevant antibacterial activity against Gram-negative and Gram-positive bacterial strains. Only [Re(CO)3(MeQ)Him] demonstrated significant action 4-fold better against Gram-negative Pseudomonas aeruginosa than the free MeHQ ligand. The cytotoxicity of the compounds was estimated using human acute promyelocytic leukemia (HL-60), ovarian (SKOV-3), prostate (PC-3), and breast (MCF-7) cancer, and breast non-cancerous (MCF-10A) cell lines. Only HQ and ClHQ ligands and [Re(CO)3(Q)Hdmpz] complex had good selectivity toward MCF-7 cell line. HL-60 cells were sensitive to all complexes (IC50 = 1.5–14 μM). Still, pure HQ and ClHQ ligands were slightly more active than the complexes.